1月27日 - ** 药物开发商 Lexeo Therapeutics LXEO.O股价盘前上涨 2%，至 7.63 美元
** 公司称任命心脏病专家 巴拉（Narinder Bhalla）博士为首席医疗官
** 公司称其研究负责人 阿德勒（Eric Adler）博士将出任Myoventive公司首席执行官，该公司专注于用RNA治疗遗传性心脏病
** 首席技术官何塞-曼努埃尔-奥特罗（José Manuel Otero）转任首席运营官；公司还聘请了两位副总裁，负责早期和晚期心脏病学项目 - LXEO
** 2025 年股价上涨约 51%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.